Fig. 3From: Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)The median survival times in the low–, moderate–, and high–risk groups were 15.8 months (reference), 12.8 months (HR, 1.44; 95% CI, 1.03–2.01; P=0.03), and 7.8 months (HR, 3.34; 95% CI, 2.40–4.64; P<0.01), respectively.Back to article page